BASEL, Switzerland & LONDON--(BUSINESS WIRE)--S.L.A. Pharma AG has announced clinically and statistically significant top-line data from their Phase 2 double blind randomised placebo controlled study. The study was designed to evaluate the safety and efficacy of 4 doses of Nalcol™, a novel oral formulation of naloxone (2.5, 5, 10, and 20 mg), in treating opioid induced constipation (OIC) in patients with persistent non-cancer pain.
